These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17703841)

  • 1. 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers.
    Jean G; Chazot C; Charra B
    Clin Nephrol; 2007 Jul; 68(1):63-4. PubMed ID: 17703841
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism.
    Tsuruta Y; Okano K; Kikuchi K; Tsuruta Y; Akiba T; Nitta K
    Clin Exp Nephrol; 2013 Feb; 17(1):120-6. PubMed ID: 22833360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients.
    Belozeroff V; Goodman WG; Ren L; Kalantar-Zadeh K
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):673-9. PubMed ID: 19261825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients.
    Owda AK; Alam MG; Kumar J
    N Engl J Med; 2004 Jul; 351(2):188-9; author reply 188-9. PubMed ID: 15247361
    [No Abstract]   [Full Text] [Related]  

  • 5. Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism.
    Yano S; Suzuki K; Sumi M; Tokumoto A; Shigeno K; Himeno Y; Sugimoto T
    J Bone Miner Metab; 2010; 28(1):49-54. PubMed ID: 19548062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study.
    Bonet J; Bayés B; Fernández-Crespo P; Casals M; López-Ayerbe J; Romero R
    Clin Nephrol; 2011 Mar; 75(3):181-7. PubMed ID: 21329627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder.
    Yokoyama K
    Clin J Am Soc Nephrol; 2009 Sep; 4(9):1405-8. PubMed ID: 19696214
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
    Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Vovan C; Chazot C
    Nephrol Ther; 2010 Apr; 6(2):105-10. PubMed ID: 20185380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients.
    Serra AL; Savoca R; Huber AR; Hepp U; Delsignore A; Hersberger M; Wüthrich RP
    Nephrol Dial Transplant; 2007 Feb; 22(2):577-83. PubMed ID: 17005527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Basic and clinical aspects of calcimimetics. The clinical effect and usefulness of Cinacalcet as a calcimimetics on three CKD-5D patients undergoing hemodialysis with refractory secondary hyperparathyroidism].
    Hanba Y; Ooura M; Negi S; Shigematsu T
    Clin Calcium; 2008 Jan; 18(1):81-8. PubMed ID: 18175876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism.
    Yajima A; Akizawa T; Tsukamoto Y; Kurihara S; Ito A;
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S38-43. PubMed ID: 19032526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
    Yuan F; Chen X; Wang C; Zhou A; Liu H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1169-1173. PubMed ID: 29093248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cinacalcet: benefit and cost.
    Cohen E
    Nephrol Dial Transplant; 2008 Apr; 23(4):1460; author reply 1460. PubMed ID: 18065795
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of cinacalcet treatment on vascular arterial stiffness among peritoneal dialysis patients with secondary hyperparathyroidism.
    Chow KM; Szeto CC; Kwan BC; Cheng PM; Pang WF; Leung CB; Li PK
    Nephrology (Carlton); 2014 Jun; 19(6):339-44. PubMed ID: 24589316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinacalcet cost and utility in dialysis patients.
    Cohen E; Uribarri J
    Semin Dial; 2005; 18(4):353-4. PubMed ID: 16076364
    [No Abstract]   [Full Text] [Related]  

  • 18. Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism.
    Hryszko T; Brzosko S; Rydzewska-Rosolowska A; Koc-Zorawska E; Mysliwiec M
    Int Urol Nephrol; 2012 Oct; 44(5):1479-86. PubMed ID: 21874285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinacalcet is efficacious in pediatric dialysis patients.
    Silverstein DM; Kher KK; Moudgil A; Khurana M; Wilcox J; Moylan K
    Pediatr Nephrol; 2008 Oct; 23(10):1817-22. PubMed ID: 18288502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients.
    Ureña Torres PA; Chanard J
    N Engl J Med; 2004 Jul; 351(2):188-9; author reply 188-9. PubMed ID: 15250062
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.